aTyr Pharma updates timing for Phase 3 efzofitimod study response
aTyr Pharma said it will provide an update on the timing of the regulatory response for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.